SCHEMBL25416397

SCHEMBL25416397

Cn1cc(-c2ccn3ncc(Br)c3c2)cn1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 4/20 0.40
AXL P30530 3/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PI4KA P42356 1/20 0.39
PIK3CG P48736 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
LRRK2 Q5S007 4/20 0.38
KIT P10721 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.37
ACVR1 Q04771 1/20 0.37
KDM1A O60341 1/20 0.36
PIM1 P11309 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
DYRK1A Q13627 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26146303 0.79 PIM1 (0.43) AXLPIM1PIM2
SCHEMBL17454339 0.78 BRD4 (0.53) FLT3PIK3CGPIM1PIM2MKNK1
SCHEMBL22792505 0.78 USP30 (0.42) FLT3AXLPIK3CDPIK3CAPIK3CB
SCHEMBL26146319 0.78 AXL (0.40) AXLPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL17438060 0.77 PIM1 (0.47) FLT3PIM1PIM2MKNK1MKNK2
SCHEMBL25200670 0.75 AXL (0.44) AXLPIK3CDPIK3CAPIK3CBLRRK2
SCHEMBL17452626 0.74 CREBBP (0.43) LRRK2PIM1PIM2MKNK1MKNK2
SCHEMBL19902676 0.74 CREBBP (0.41) FLT3KITPIM1PIM2MKNK1
SCHEMBL25619521 0.74 FLT3 (0.44) FLT3AXLPIK3CDPIK3CAPIK3CB
SCHEMBL26146282 0.72 MET (0.48) FLT3AXLPIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2025-04-24 US disclosed
EP-4430047-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2024-09-18 EP disclosed
CN-118475580-A Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof 普罗根托斯治疗公司 2024-08-09 CN disclosed
WO-2023081923-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Frequency Therapeutics, Inc. (US) 2023-05-11 WO disclosed
WO-2023081923-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Frequency Therapeutics, Inc. (US) 2023-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PDGFRB, PDGFRA, PDGFA FLT3 30/4885AXL 672/4885PIK3CD 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.